Harbin Medisan Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Harbin Medisan Pharmaceutical's earnings have been declining at an average annual rate of -22.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 17.6% per year. Harbin Medisan Pharmaceutical's return on equity is 2.3%, and it has net margins of 4.9%.
Key information
-22.1%
Earnings growth rate
-22.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -17.6% |
| Return on equity | 2.3% |
| Net Margin | 4.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Harbin Medisan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,091 | 53 | 537 | 117 |
| 31 Dec 23 | 1,187 | 74 | 595 | 113 |
| 30 Sep 23 | 1,189 | 69 | 635 | 104 |
| 30 Jun 23 | 1,161 | 62 | 655 | 104 |
| 31 Mar 23 | 1,114 | 71 | 633 | 94 |
| 01 Jan 23 | 1,028 | 30 | 595 | 89 |
| 30 Sep 22 | 1,000 | -167 | 665 | 93 |
| 30 Jun 22 | 977 | -215 | 663 | 89 |
| 31 Mar 22 | 972 | -214 | 675 | 94 |
| 01 Jan 22 | 946 | 351 | 669 | 100 |
| 30 Sep 21 | 1,080 | 547 | 636 | 102 |
| 30 Jun 21 | 1,186 | 588 | 667 | 105 |
| 31 Mar 21 | 1,280 | 561 | 717 | 113 |
| 31 Dec 20 | 1,339 | 29 | 738 | 112 |
| 30 Sep 20 | 1,437 | 49 | 783 | 130 |
| 30 Jun 20 | 1,603 | 88 | 901 | 125 |
| 31 Mar 20 | 1,890 | 156 | 1,098 | 112 |
| 31 Dec 19 | 2,102 | 177 | 1,287 | 112 |
| 30 Sep 19 | 2,228 | 175 | 1,490 | 81 |
| 30 Jun 19 | 2,303 | 178 | 1,598 | 81 |
| 31 Mar 19 | 2,201 | 197 | 1,561 | 82 |
| 01 Jan 19 | 2,173 | 206 | 1,546 | 79 |
| 30 Sep 18 | 2,057 | 237 | 1,426 | 76 |
| 30 Jun 18 | 1,762 | 244 | 1,110 | 110 |
| 31 Mar 18 | 1,451 | 219 | 810 | 88 |
| 31 Dec 17 | 1,149 | 181 | 541 | 69 |
| 30 Sep 17 | 895 | 186 | 289 | 54 |
| 31 Dec 16 | 761 | 175 | 249 | 0 |
| 31 Dec 15 | 722 | 166 | 232 | 0 |
| 31 Dec 14 | 682 | 147 | 207 | 0 |
| 31 Dec 13 | 601 | 104 | 169 | 0 |
Quality Earnings: 002900 has a high level of non-cash earnings.
Growing Profit Margin: 002900's current net profit margins (4.9%) are lower than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002900's earnings have declined by 22.1% per year over the past 5 years.
Accelerating Growth: 002900's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002900 had negative earnings growth (-24.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.5%).
Return on Equity
High ROE: 002900's Return on Equity (2.3%) is considered low.